Novel Ocular Lubricant Containing an Intelligent Delivery System: Details of Its Mechanism of Action

2010 ◽  
pp. 139-147 ◽  
Author(s):  
Clark Springs
Keyword(s):  
Delivery System ◽  
Mechanism Of Action

Saphris: Does a unique delivery system equal a unique drug?

2011 ◽  
Vol 1 (6) ◽  
pp. 133-134
Author(s):  
Kelly N. Gable
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Delivery System ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

1004: In-Vivo Transfection of the Rat Corpus Cavernosum Using a Non-Viral, Linear Polyethylenimine Gene Delivery System: A Novel Application

2006 ◽  
Vol 175 (4S) ◽  
pp. 323-324 ◽  
Author(s):  
Joseph Dall'era ◽  
Sweaty Koul ◽  
Jesse Mills ◽  
Jeremy Myers ◽  
Randall B. Meacham ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Delivery System ◽  
Corpus Cavernosum ◽  
Gene Delivery System ◽  
System A ◽  
In Vivo Transfection ◽  
Linear Polyethylenimine

First clinical experience with the Multi-LOC multiple stent delivery system for focal stenting in long femoro-popliteal lesions

VASA ◽  
2017 ◽  
Vol 46 (6) ◽  
pp. 452-461 ◽  
Author(s):  
Klaus Amendt ◽  
Ulrich Beschorner ◽  
Matthias Waliszewski ◽  
Martin Sigl ◽  
Ralf Langhoff ◽  
...  
Keyword(s):  
Observational Study ◽  
Clinical Experience ◽  
Delivery System ◽  
Target Lesion ◽  
Lesion Length ◽  
Elastic Recoil ◽  
Delivery Device ◽  
Clinical Assessments ◽  
Balloon Catheters ◽  
Considerable Length

Abstract. Background: The purpose of this observational study is to report the six-month clinical outcomes with a new multiple stent delivery system in patients with femoro-popliteal lesions. Patients and methods: The LOCOMOTIVE study is an observational multicentre study with a primary endpoint target lesion revascularization (TLR) rate at six months. Femoro-popliteal lesions were prepared with uncoated and/or paclitaxel-coated peripheral balloon catheters. When flow limiting dissections, elastic recoil or recoil due to calcification required stenting, up to six short stents per delivery device, each 13 mm in length, were implanted. Sonographic follow-ups and clinical assessments were scheduled at six months. Results: For this first analysis, a total of 75 patients 72.9 ± 9.2 years of age were enrolled. The majority of the 176 individually treated lesions were in the superficial femoral artery (76.2 %, 134/176) whereas the rate of TASC C/D amounted to 51.1 % (90/176). The total lesion length was 14.5 ± 9.0 cm with reference vessel diameters of 5.6 ± 0.7 mm. Overall 47 ± 18 % of lesion lengths could be saved from stenting. At six months, the patency was 90.7 % (68/75) and all-cause TLR rates were 5.3 % (4/75) in the overall cohort. Conclusions: The first clinical experience at six months suggests that the MSDS strategy was safe and effective to treat femoro-popliteal lesions of considerable length (14.5 ± 9.0 cm). Almost half of the lesion length could be saved from stenting while patency was high and TLR rates were acceptably low.

Combining a global health budget with a market-driven delivery system: Can it be done?

1993 ◽  
Vol 48 (3) ◽  
pp. 270-276 ◽  
Author(s):  
Jeff Bingaman ◽  
Robert G. Frank ◽  
Carrie L. Billy
Keyword(s):  
Global Health ◽  
Delivery System ◽  
Health Budget ◽  
Market Driven
Sign in / Sign up

Export Citation Format

Share Document